×
MacroGenics Net Income 2012-2024 | MGNX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
MacroGenics net income from 2012 to 2024. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Historical Chart (TTM)
Quarterly
Quarterly - YOY Change
Annual
Annual % Change
Related Stocks
Company Name
Market
Cap
Abbott Laboratories (ABT)
$229.2B
Boston Scientific (BSX)
$155.9B
Stryker (SYK)
$148.3B
EssilorLuxottica (ESLOY)
$140.1B
Medtronic (MDT)
$111.6B
Lonza Group Ag (LZAGY)
$46.2B
Haleon (HLN)
$45.2B
GE HealthCare Technologies (GEHC)
$42.3B
Agilent Technologies (A)
$39.1B
ResMed (RMD)
$34.4B
Terumo (TRUMY)
$26.6B
Koninklijke Philips (PHG)
$23.5B
Zimmer Biomet Holdings (ZBH)
$20.6B
Insulet (PODD)
$19.9B
Baxter (BAX)
$15.7B
Sunny Optical Technology (SNPTF)
$11.3B
Smith & Nephew SNATS (SNN)
$11.2B
BellRing Brands (BRBR)
$9.9B
Demant (WILYY)
$7.9B
Bio-Rad Laboratories (BIO)
$7.9B
Lantheus Holdings (LNTH)
$5.7B
Prestige Consumer Healthcare (PBH)
$4.2B
ICU Medical (ICUI)
$4B
Envista Holdings (NVST)
$3.7B
Perrigo (PRGO)
$3.4B
Haemonetics (HAE)
$3.2B
Shandong Weigao Medical Polymer (SHWGF)
$3B
GN Store Nord (GNNDY)
$2.9B
QuidelOrtho (QDEL)
$2.8B
LeMaitre Vascular (LMAT)
$2.3B